These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 23077931

  • 1. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM, Niţă O, Graur LI, Mihalache L, Popescu DS, Graur M.
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [Abstract] [Full Text] [Related]

  • 2. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, Asia-Pacific Working Party for NAFLD.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [Abstract] [Full Text] [Related]

  • 3. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [Abstract] [Full Text] [Related]

  • 4. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
    Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N.
    Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
    [Abstract] [Full Text] [Related]

  • 5. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.
    Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK.
    Am J Gastroenterol; 2009 Apr; 104(4):861-7. PubMed ID: 19293782
    [Abstract] [Full Text] [Related]

  • 6. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ.
    Diabetes Metab Res Rev; 2006 Apr; 22(6):437-43. PubMed ID: 16832839
    [Abstract] [Full Text] [Related]

  • 7. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G.
    Dig Dis; 2010 Apr; 28(1):210-3. PubMed ID: 20460913
    [Abstract] [Full Text] [Related]

  • 8. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.
    Moore JB.
    Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939
    [Abstract] [Full Text] [Related]

  • 9. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
    Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A.
    J Assoc Physicians India; 2009 Mar; 57():201-4. PubMed ID: 19588647
    [Abstract] [Full Text] [Related]

  • 10. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG.
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [Abstract] [Full Text] [Related]

  • 11. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

  • 12. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [Abstract] [Full Text] [Related]

  • 13. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S, Younossi ZM.
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [Abstract] [Full Text] [Related]

  • 14. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
    Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML.
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
    [Abstract] [Full Text] [Related]

  • 15. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ, Mensink RP.
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [Abstract] [Full Text] [Related]

  • 16. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response.
    Younossi ZM, McCullough AJ.
    Liver Int; 2009 Mar; 29 Suppl 2():3-12. PubMed ID: 19187068
    [Abstract] [Full Text] [Related]

  • 17. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG, Cao HX.
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [Abstract] [Full Text] [Related]

  • 18. Hepatic steatosis and vascular disease.
    Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, Lupascu A, Di Giorgio A, Flore R, Pola P, Gasbarrini G, Gasbarrini A, Tondi P, Grieco A.
    Eur Rev Med Pharmacol Sci; 2005 Dec; 9(5):269-71. PubMed ID: 16231588
    [Abstract] [Full Text] [Related]

  • 19. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Lu H, Zeng L, Liang B, Shu X, Xie D.
    Arch Med Res; 2009 Oct; 40(7):571-5. PubMed ID: 20082871
    [Abstract] [Full Text] [Related]

  • 20. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease.
    Friis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E.
    Scand J Gastroenterol; 2004 Sep; 39(9):864-9. PubMed ID: 15513385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.